我要投票 21金维他在补铁锌硒行业中的票数:287
· 外 推 电 报 ·
2025-02-24 07:26:49 星期一

【21金维他是哪个国家的品牌?】

21金维他是什么牌子?「21金维他」是杭州赛诺菲民生健康药业有限公司旗下著名品牌。该品牌发源于浙江,由创始人张海敏在2009期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。

外推网助力21金维他品牌出海!通过在本页面挂载21金维他品牌的产品链接和联系邮箱,可以提高21金维他产品曝光!跨境电商爆单神器,目前只要100元/年哦~

21金维他,1984年上市,是中国率先上市的多维元素产品。根据中国人营养状况和饮食习惯科学配比,均衡补充人体所需的21维生素和矿物质,采用国际一流生产线生产的健康产品。

“21金维他”是一种主要原料由21种维生素和微量元素组成的药品,是一种高级的维生素补充剂。21金维他里面含有维生素C和E,维生素C可以美白,增强抵抗力,抗衰老,维生素E有软化血管,抗衰老,美白,可以用于美容,祛除一定的斑痕。

杭州民生药业有限公司创建于1926年,是中国最早的四大西药厂之一。80余年来,民生药业一直专注于西药制药产业,见证了中国整个西药制药的历史。2006年被商务部评为第一批“中华老字号”企业。

公司主要生产处方药(抗肿瘤药、抗乙肝、心血管类)、OTC(含维生素和保健品类)、大输液(包括特种输液)以及原料药等四大品类的品种。21金维他在2004年被认定为“中国驰名商标”,并确立了在国内多维元素补充剂市场的领军品牌地位。另外公司在抗肿瘤及大输液等领域享有较高的市场声誉。

公司具有较强的产品开发能力和先进的质量保证体系。粉针剂、冻干粉针剂、大容量注射剂和片剂已获药品GMP证书。同时公司被杭州市政府有关部门确定为高效化学原料及各类新型制剂的研究和生产基地的高新技术企业。

80余年的积累和发展,民生药业成为了一家专业化、负责任的现代化制药公司,公司在2002年至2006年间成功实施了跳跃式发展战略;从2007年开始全面实施的国际化发展战略,将引领企业走向新的辉煌。打造一个经久不衰、生生不息、充满青春活力的百年民生是我们的追求!

杭州赛诺菲民生健康药业有限公司成立于2010年,是由全球领先的多元化医药健康企业赛诺菲与杭州民生药业集团共同组建的健康药业领域合资企业。这标志着赛诺菲正式进军充满活力的中国非处方药市场,同时也是全球第二大的非处方药市场。

作为全球领先的多元化医药健康企业,赛诺菲在健康药业领域通过不断并购,扩大其在全球的实力。进入中国健康药业市场成为赛诺菲支持中国预防保健事业的又一支柱。赛诺菲与长期合作的伙伴民生药业成立合资企业,旨在使21金维他®等品牌覆盖到各个市场,让更多的中国百姓享受到健康保障。

英文翻译:Kingvita, launched in 1984, is the first multi-dimensional element product to be launched in China. According to the scientific proportion of Chinese Nutrition and diet habits, we should supplement the 21 vitamins and minerals needed by human body in a balanced way, and adopt the health products produced by the world-class production line. "21 jinvita" is a kind of medicine composed of 21 kinds of vitamins and microelements, which is a kind of advanced vitamin supplement. Jinvita contains vitamin C and E. vitamin C can whiten, enhance resistance and resist aging. Vitamin E can soften blood vessels, resist aging and whiten. It can be used for beauty and remove certain spots. Founded in 1926, Hangzhou Minsheng Pharmaceutical Co., Ltd. is one of the first four Western pharmaceutical factories in China. For more than 80 years, Minsheng pharmaceutical industry has been focusing on Western pharmaceutical industry, witnessing the history of the whole western pharmaceutical industry in China. In 2006, it was awarded the first batch of "Chinese time-honored brand" enterprises by the Ministry of Commerce. The company mainly produces prescription drugs (anti-tumor drugs, anti hepatitis B drugs, cardiovascular drugs), OTC (including vitamins and health care products), large infusion (including special infusion) and APIs. In 2004, kingvita was recognized as "China's well-known trademark" and established its leading brand position in the domestic multi-dimensional element supplement market. In addition, the company enjoys a high market reputation in the fields of anti-tumor and infusion. The company has strong product development ability and advanced quality assurance system. Powder injection, freeze-dried powder injection, large volume injection and tablet have obtained GMP certificate. At the same time, the company is determined by the relevant departments of Hangzhou municipal government as a high-tech enterprise in the research and production base of high-efficiency chemical raw materials and various new preparations. With more than 80 years of accumulation and development, Minsheng pharmaceutical industry has become a professional and responsible modern pharmaceutical company. From 2002 to 2006, Minsheng pharmaceutical successfully implemented the leaping development strategy. The international development strategy, which has been fully implemented since 2007, will lead the enterprise to a new glory. It is our pursuit to build a centenary people's livelihood that is enduring, endless and full of youth and vitality! Hangzhou Sanofi Minsheng Health Pharmaceutical Co., Ltd., founded in 2010, is a joint venture in the field of health pharmaceutical jointly established by Sanofi, a global leading diversified pharmaceutical and health enterprise, and Hangzhou Minsheng Pharmaceutical Group. This marks Sanofi's official entry into the dynamic Chinese over-the-counter drug market, which is also the second largest over-the-counter drug market in the world. As a leading diversified medical and health enterprise in the world, Sanofi expands its global strength through continuous M & A in the field of health medicine. Entering the Chinese health pharmaceutical market has become another pillar of Sanofi's support for China's prevention and health care. Sanofi has set up a joint venture with Minsheng pharmaceutical, a long-term partner, aiming to make 21 jinvita ® and other brands reach all markets and more Chinese people enjoy health protection.

本文链接: https://www.waitui.com/brand/0d30c126b.html 联系电话:请联系客服添加

千城特选小程序码

7×24h 快讯

一汽大众ID.系列部分车型官降至高5.5万元

一汽-大众宣布对旗下ID.系列部分车型进行降价,最高降幅达5.5万元。此次降价活动涉及ID.4 CROZZ和ID.6 CROZZ两款车型,无门槛一口价分别为13.99万元和19.59万元起,还可叠加官方置换补贴至高1万元、国家置换补贴至高2万元。(财联社)

2小时前

2025年中央一号文件发布

36氪获悉,2025年中央一号文件2月23日发布,《中共中央 国务院关于进一步深化农村改革 扎实推进乡村全面振兴的意见》提出,以改革开放和科技创新为动力,巩固和完善农村基本经营制度,深入学习运用“千万工程”经验,确保国家粮食安全,确保不发生规模性返贫致贫,提升乡村产业发展水平、乡村建设水平、乡村治理水平,千方百计推动农业增效益、农村增活力、农民增收入,为推进中国式现代化提供基础支撑,这是党的十八大以来第13个指导“三农”工作的中央一号文件。

2小时前

海天味业:公司发行H股备案申请材料获中国证监会接收

36氪获悉,海天味业公告称,公司已于2025年1月13日向香港联交所递交了发行H股股票并在香港联交所主板挂牌上市的申请。公司已向中国证监会报送了关于公司本次发行的备案申请材料并于近日获中国证监会接收。该事项仍存在不确定性,公司将根据进展情况及时履行信息披露义务。

2小时前

山河药辅:股东复星医药拟减持不超过3%公司股份

36氪获悉,山河药辅发布公告,股东上海复星医药产业发展有限公司因经营需要,计划以集中竞价和大宗交易方式合计减持公司股份不超过697.8万股,即不超过公司总股本的3%。

2小时前

镁伽科技正式推出LABILLION™实验室智慧管理平台,并于线上发布

36氪获悉,近日镁伽科技正式推出LABILLION™实验室智慧管理平台,并于线上发布。作为镁伽在“AI for Science(AI4S)”领域的新成果,LABILLION™以AI与自动化技术为核心,针对生命科学研发中长期存在的数据孤岛、系统僵化、流程低效等痛点,为科学家提供从实验设计到数据分析的全链路智能支持,助力科研创新效率的提升。

2小时前

本页详细列出关于全元康的品牌信息,含品牌所属公司介绍,全元康所处行业的品牌地位及优势。
咨询